Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).

Authors:
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C and 2 more

Journal:
Theranostics

Publication Year: 2024

DOI:
10.7150/thno.88619

PMCID:
PMC10750196

PMID:
38164147

Journal Information

Full Title: Theranostics

Abbreviation: Theranostics

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Diagnostic Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing Interests: The authors have declared that no competing interest exists."

Evidence found in paper:

"This study was supported by the National University of Singapore Start-up Grant (NUHSRO/2021/097/Startup/13; NUHSRO/2020/133/Startup/08), NUS Theranostics Center of Excellence (NUHSRO/2023/008/NUSMed/TCE/LOA), NUS School of Medicine Nanomedicine Translational Research Programme (NUHSRO/2021/034/TRP/09/Nanomedicine), National Medical Research Council (NMRC) CS-IRG NIG Grant (MOH-001254-01), NMRC Centre Grant Programme (CG21APR1005), and the International Centers for Precision Oncology (ICPO) Foundation."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025